PIK3CA and small cell lung carcinoma: In addition, other acquired resistance mechanism has been reported; including the development of small cell lung cancer or squamous cell transformation, second point mutations (D761Y or L747S), MET amplification, acquired PIK3CA or BRAF mutation, and epithelial-to-mesenchymal transition [9, 10, 13–16].